Cargando…
Delivery of chemo-sensitizing siRNAs to HER2(+)-breast cancer cells using RNA aptamers
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers....
Autores principales: | Thiel, Kristina W., Hernandez, Luiza I., Dassie, Justin P., Thiel, William H., Liu, Xiuying, Stockdale, Katie R., Rothman, Alissa M., Hernandez, Frank J., McNamara, James O., Giangrande, Paloma H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401474/ https://www.ncbi.nlm.nih.gov/pubmed/22467215 http://dx.doi.org/10.1093/nar/gks294 |
Ejemplares similares
-
Rapid Identification of Cell-Specific, Internalizing RNA Aptamers with Bioinformatics Analyses of a Cell-Based Aptamer Selection
por: Thiel, William H., et al.
Publicado: (2012) -
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
por: Kruspe, Sven, et al.
Publicado: (2017) -
Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells
por: Zhou, Jiehua, et al.
Publicado: (2013) -
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
por: Hernandez, Luiza I., et al.
Publicado: (2013) -
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates
por: Cuellar, Trinna L., et al.
Publicado: (2015)